{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:19:49Z","timestamp":1772792389218,"version":"3.50.1"},"reference-count":7,"publisher":"American Society of Consultant Pharmacists","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2011,8,1]]},"DOI":"10.4140\/tcp.n.2011.579","type":"journal-article","created":{"date-parts":[[2011,8,13]],"date-time":"2011-08-13T01:13:42Z","timestamp":1313198022000},"page":"579-582","source":"Crossref","is-referenced-by-count":8,"title":["Comment on the Potential Utility of the New Atypical Antipsychotic Lurasidone in the Geriatric Population"],"prefix":"10.4140","volume":"26","author":[{"given":"David R. P.","family":"Guay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2011,8,12]]},"reference":[{"key":"1","unstructured":"Lurasidone hydrochloride (Latuda\u00ae) tablets prescribing information. Fort Lee, NJ: Sunovion Pharmaceuticals; November 2010."},{"key":"2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytriptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"T Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbr.2007.12.006","article-title":"Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets","volume":"195","author":"AV Terry Jr","year":"2008","journal-title":"Behav Brain Res"},{"key":"4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbr.2007.08.012","article-title":"Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats","volume":"186","author":"T Enomoto","year":"2008","journal-title":"Behav Brain Res"},{"key":"5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2007.06.058","article-title":"Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test","volume":"572","author":"T Ishiyama","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: a double-blind, placebocontrolled trial","volume":"70","author":"M Nakamura","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"7","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543780903286388","article-title":"Lurasidone: a new drug in development for schizophrenia","volume":"18","author":"JM Meyer","year":"2009","journal-title":"Expert Opin Invest Drugs"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T01:30:25Z","timestamp":1560475825000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2011\/00000026\/00000008\/art00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,1]]},"references-count":7,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8,1]]}},"alternative-id":["0016V168V7LX52N8"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2011.579","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8,1]]}}}